More Cheer For Biocon-Mylan As Brazil Clears Biosimilar Trastuzumab

Biocon and Mylan have received approval in Brazil for the first biosimilar version of Roche’s Herceptin (trastuzumab). The partners hope to provide an “affordable” option, expanding access to the product in the Latin American nation.